论文部分内容阅读
目的:观察充血性心力衰竭(CHF)患者口服β受体阻断剂美托洛尔和卡维地洛后血浆血管性假血友病因子(vWF)及肿瘤坏死因子-α(TNF-α)的改变,并探讨其改变的临床意义。方法:63例CHF患者随机给予美托洛尔或卡维地洛达目标剂量后12周,观察血浆vWF及TNF-α浓度的变化。30例体检正常健康者作为对照组。血浆vWF采用酶标法测定,TNF-α采用生物活性法测定。结果:2组CHF患者基础血浆vWF和TNF-α浓度高于健康对照组(P<0.01);服药4周后,美托洛尔组和卡维地洛组血浆vWF和TNF-α浓度下降(P<0.05),12周后进一步下降(P<0.01)。结论:β受体阻断剂能下调CHF患者血浆vWF及TNF-α浓度。
OBJECTIVE: To observe the changes of plasma von Willebrand factor (vWF) and tumor necrosis factor-α (TNF-α) levels after oral inhaled β-blockers metoprolol and carvedilol in patients with congestive heart failure (CHF) Change, and explore the clinical significance of its change. Methods: Sixty-three patients with CHF were randomly assigned to metoprolol or carvedilol for 12 weeks. The changes of vWF and TNF-α in plasma were observed. 30 cases of normal physical examination as a control group. Plasma vWF was determined by enzyme-linked immunosorbent assay (ELISA). TNF-α was determined by bioactivity assay. Results: The plasma concentrations of vWF and TNF-α in CHF patients were higher than those in healthy controls (P <0.01). After 4 weeks of treatment, the concentrations of vWF and TNF-α in metoprolol and carvedilol groups were decreased P <0.05), and further decreased after 12 weeks (P <0.01). Conclusion: β-blockers can down-regulate vWF and TNF-α in CHF patients.